Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Bacterium or component thereof or substance produced by said...
Reexamination Certificate
2005-12-13
2005-12-13
Saucier, Sandra E. (Department: 1651)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Bacterium or component thereof or substance produced by said...
C424S236100, C424S234100, C424S184100, C424S247100
Reexamination Certificate
active
06974579
ABSTRACT:
The present invention provides methods for improving blood supply through a grafted blood vessel. In some embodiments, the methods comprise the step of locally administering a botulinum toxin to the grafted blood vessel, thereby improving blood supply through the grafted blood vessel.
REFERENCES:
patent: 5376376 (1994-12-01), Li
patent: 5437291 (1995-08-01), Pasricha et al.
patent: 5670484 (1997-09-01), Binder
patent: 5714468 (1998-02-01), Binder
patent: 5766605 (1998-06-01), Sanders et al.
patent: 5989545 (1999-11-01), Foster et al.
patent: 6063768 (2000-05-01), First
patent: 6139845 (2000-10-01), Donovan
patent: 6265379 (2001-07-01), Donovan
patent: 6299893 (2001-10-01), Schwartz et al.
patent: 6306423 (2001-10-01), Donovan et al.
patent: 6312708 (2001-11-01), Donovan
patent: 6358926 (2002-03-01), Donovan
patent: 6423319 (2002-07-01), Brooks et al.
patent: 6458365 (2002-10-01), Aoki et al.
patent: 6464986 (2002-10-01), Aoki et al.
patent: 6579847 (2003-06-01), Unger
patent: 6767544 (2004-07-01), Brooks et al.
patent: WO 01/10458 (2001-02-01), None
patent: WO 03/084567 (2003-10-01), None
Costello RB et al., eds. Webster's College Dictionary, 1991, Random House Inc. p. 579.
U.S. Appl. No. 09/371,354, filed Aug. 10, 1999, Stephen Donovan.
U.S. Appl. No. 10/114,740, filed Apr. 1, 2002, Greg Brooks.
U.S. Appl. No. 10/194,805, filed Jul. 11, 2002, Stephen Donovan.
Bigalke H., et al.,Botulinum A Neurotoxin Inhibits Non-Cholinergic Synaptic Transmission in Mouse Spinal Cord Neurons in Culture, Brain Research 360;318-324:1985.
Bigalke H., et al.,Tetanus Toxin and Botulinum A Toxin Inhibit Release and Uptake of Various Transmitters, as Studied with Particulate Preparations From Rat Brain and Spinal Cord, Naunyn-Schmiedeberg's Arch Pharmacol 316;244-251;1981.
Binz T. et al.,The Complete Sequence of Botulinum Neurotoxin Type A and Comparison with Other Clostridial Neurotoxins, J Biological Chemistry 265(16);9153-9158:1990.
Bushara K.,Botulinum toxin and rhinorrhea, Otolaryngol Head Neck Surg 1996;114(3):507.
Duggan et al.,A Survey of Botulinum neurotoxin substrate expression in cells; Mov Disord, 10(3):376:1995.
Gonelle-Gispert et al.,Snap-25a and -25b isoforms are both expressed in insulin-secreting cells and can function in insulin secretion; Biochem J 1, 339 (pt 1):159-65:1999.
Habermann E., et al.,Tetanus Toxin and Botulinum A and C Neurotoxins Inhibit Noradrenaline Release From Cultured Mouse Brain, J Neurochem 51(2);522-527:1988.
Habermann E.,Inhibition by Tetanus and Botulinum A Toxin of the release of [3H]Noradrenaline and [3H]GABA From Rat Brain Homogenate, Experientia 44;224-226:1988.
Harrison's Principles of Internal Medicine(1998), edited by Anthony Fauci et al., 14th edition, published by McGraw Hill.
Jankovic J. et al.,Therapy With Botulinum Toxin, Marcel Dekker, Inc., (1994), p. 5, 150.
Moro E., et al,Suppression of syncopes after botulinum toxin treatment, Mov Disord 2002;17(Suppl 5):S242 ABS P780.
Moyer E et al.,Botulinum Toxin Type B: Experimental and Clinical Experience, being chapter 6, pp. 71-85 of “Therapy With Botulinum Toxin”, edited by Jankovic, J. et al. (1994), Marcel Dekker, Inc.
Naumann et al.,Botulinum toxin type A in the treatment of focal, axillary and palmar hyperhidrosis and other hyperhidrotic conditions; European J. Neurology 6 (Supp 4): S111-S1150:1999.
Pearce, L.B.,Pharmacologic Characterization of Botulinum Toxin For Basic Science and Medicine, Toxicon 35(9);1373-1412 at 1393.
Ragona et al., Management of Parotid Sialocele with Botulinum Toxin; The Laryngoscope109:1344-1346:1999.
Sanchez-Prieto, J., et al.,Botulinum Toxin A Blocks Glutamate Exocytosis From Guinea Pig Cerebral Cortical Synaptosomes, Eur J. Biochem 165;675-681:1897.
Sterodimas, A., et al.,Successful use of botulinum toxin-A for the treatment ofneck and anterior chest wall flushing, Clinical and Experimental Dermatology, 2003 Blackwell Publishing Ltd., vol. 28, p. 592-594.
Schantz, E.J., et al,Properties and use of Botulinum toxin and Other Microbial Neurotoxins in Medicine, Microbiol Rev. 56;80-99:1992.
Singh,Critical Aspects of Bacterial Protein Toxins, pp. 63-84 (chapter 4) of Natural Toxins II, edited by B.R. Singh et al., Plenum Press, New York (1976).
Sloop et al.,Reconstituted Botulinum toxin type A does not lose potency in humans if it is refrozen or refrigerated for 2 weeks before use; Neurology, 48:249-53:1997.
Tugnoli V., et al.,The role of gustatory flushing in Frey's syndrome and its treatment with botulinum toxin type A, Clin Auton Res 2002;12(3):174-178.
Kellogg, Jr., Dean L., et al.,Cutaneous Active Vasodilation in Humans is Mediated by Cholinergic Nerve Cotransmission, vol. 77(6), Dec. 1995, American Heart Association, Inc., Lippincott Williams & Wilkins, pp. 1222-1228.
Brin Mitchell F.
Naumann Markus K.
Allergan Inc.
Barnhart Lora E
Donovan Stephen
Saucier Sandra E.
LandOfFree
Methods for treating vascular disorders does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for treating vascular disorders, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for treating vascular disorders will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3520550